Table 2.
For each treatment group, amount of OVA delivered, OVA encapsulation efficiency, OVA:polymer ratio, amount of DX delivered, DX encapsulation efficiency, DX:polymer ratio, amount of polymer mass delivered and endotoxin contents are presented. Data are shown as mean ± SD (n=3-8 SCs); NA=not applicable.
| Treatment Groups (8 mice per treatment group) | ||||||
|---|---|---|---|---|---|---|
| PLGA SC | PLGA OVA SC | PLGA DX SC | PLGA DX OVA SC |
PBS | CFA | |
| OVA delivered (μg) |
NA | 33.9 ± 9.1 | NA | 35.0 ± 22.7 | 34.4 | 34.4 |
| Percent OVA encapsulation efficiency |
NA | 0.14 ± 0.02% | NA | 0.14 ± 0.04% | NA | NA |
| OVA to polymer ratio (mg/mg) |
NA | 0.003 ± 0.001 | NA | 0.003 ± 0.001 | NA | NA |
| DX delivered (μg) | NA | NA | 5.3 ± 1.4 | 15.0 ± 8.7 | NA | NA |
| Percent DX encapsulation efficiency |
NA | NA | 13 ± 3% | 31 ± 7% | NA | NA |
| DX to polymer ratio (mg/mg) |
NA | NA | 0.0006 ± 0.0001 |
0.0014 ± 0.0003 |
NA | NA |
| Polymer mass delivered (mg) |
11.9 ± 3.9 | 11.3 ± 2.5 | 11.3 ± 2.1 | 10.6 ± 2.0 | NA | NA |
| Endotoxin (EU/ml) | 0.12 ± 0.02 | >1.0 | <0.1 | >1.0 | NA | NA |